We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

The challenge of developing robust drugs to overcome resistance

dc.contributor.authorAnderson, Amy C.
dc.contributor.authorPollastri, Michael P.
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorPeet, Norton P.
dc.date2022-08-11T08:08:00.000
dc.date.accessioned2022-08-23T15:38:45Z
dc.date.available2022-08-23T15:38:45Z
dc.date.issued2011-09-26
dc.date.submitted2011-11-22
dc.identifier.citationDrug Discov Today. 2011 Sep;16(17-18):755-61. Epub 2011 Jul 19. <a href="http://dx.doi.org/10.1016/j.drudis.2011.07.001">Link to article on publisher's site</a>
dc.identifier.issn1359-6446 (Linking)
dc.identifier.doi10.1016/j.drudis.2011.07.001
dc.identifier.pmid21784168
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26002
dc.description.abstractDrug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=21784168&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.drudis.2011.07.001
dc.subjectDrug Design
dc.subjectDrug Resistance, Viral
dc.subjectHIV Protease Inhibitors
dc.subjectHIV-1
dc.subjectMolecular Targeted Therapy
dc.subjectBiochemistry, Biophysics, and Structural Biology
dc.subjectMicrobiology
dc.titleThe challenge of developing robust drugs to overcome resistance
dc.typeJournal Article
dc.source.journaltitleDrug discovery today
dc.source.volume16
dc.source.issue17-18
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/bmp_pp/132
dc.identifier.contextkey2367981
html.description.abstract<p>Drug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.</p>
dc.identifier.submissionpathbmp_pp/132
dc.contributor.departmentInstitute for Drug Resistance
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages755-61


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record